{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:12:07Z","timestamp":1779203527972,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Laboratory of Data Discovery for Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40264-025-01645-3","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:44:43Z","timestamp":1768808683000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5345-2471","authenticated-orcid":false,"given":"Zixuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-7185","authenticated-orcid":false,"given":"Qiuyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-2381","authenticated-orcid":false,"given":"Julian","family":"Matthewman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-2615","authenticated-orcid":false,"given":"John","family":"Tazare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-9794","authenticated-orcid":false,"given":"Sara Benitez","family":"Majano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-7759","authenticated-orcid":false,"given":"Jeremy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-378X","authenticated-orcid":false,"given":"Ka Shing","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8726","authenticated-orcid":false,"given":"Celine S. L.","family":"Chui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W. Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-8757","authenticated-orcid":false,"given":"Krishnan","family":"Bhaskaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-1406","authenticated-orcid":false,"given":"Ian J.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-7333","authenticated-orcid":false,"given":"Angel Y. S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1645_CR1","unstructured":"National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. 30 June 2021. https:\/\/www.nice.org.uk\/guidance\/ng196. Accessed 22 Apr 2024."},{"key":"1645_CR2","unstructured":"National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. 13 August 2019. https:\/\/www.nice.org.uk\/guidance\/ng89. Accessed 22 Apr 2024."},{"issue":"4","key":"1645_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355.","journal-title":"Circulation"},{"issue":"2","key":"1645_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s11239-021-02416-4","volume":"52","author":"S Afzal","year":"2021","unstructured":"Afzal S, Zaidi STR, Merchant HA, et al. Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting. J Thromb Thrombolysis. 2021;52(2):646\u201353.","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"1645_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37288","volume":"4","author":"KM Wheelock","year":"2021","unstructured":"Wheelock KM, Ross JS, Murugiah K, et al. Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries. JAMA Netw Open. 2021;4(12):e2137288.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1645_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-020-5072-3","volume":"20","author":"Z Yu","year":"2020","unstructured":"Yu Z, Yu L, Shan C. Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012\u20132017. BMC Health Serv Res. 2020;20(1):1\u20136.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"1645_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018180","volume":"8","author":"L Huiart","year":"2018","unstructured":"Huiart L, Ferdynus C, Renoux C, et al. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open. 2018;8(3):e018180.","journal-title":"BMJ Open"},{"key":"1645_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40264-020-00961-0","volume":"43","author":"X Li","year":"2020","unstructured":"Li X, Pathadka S, Man KKC, et al. Comparative outcomes between direct oral anticoagulants, warfarin, and antiplatelet monotherapy among Chinese patients with atrial fibrillation: a population-based cohort study. Drug Saf. 2020;43:1023\u201333.","journal-title":"Drug Saf"},{"issue":"18","key":"1645_CR9","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","volume":"75","author":"A Kirane","year":"2015","unstructured":"Kirane A, Ludwig KF, Sorrelle N, et al. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Res. 2015;75(18):3699\u2013705.","journal-title":"Cancer Res"},{"issue":"18","key":"1645_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCULATIONAHA.119.041949","volume":"140","author":"JW Eikelboom","year":"2019","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Bleeding and new cancer diagnosis in patients with atherosclerosis. Circulation. 2019;140(18):1451\u20139.","journal-title":"Circulation"},{"issue":"12","key":"1645_CR11","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamainternmed.2017.5512","volume":"177","author":"GS Haaland","year":"2017","unstructured":"Haaland GS, Falk RS, Straume O, et al. Association of warfarin use with lower overall cancer incidence among patients older than 50\u00a0years. JAMA Intern Med. 2017;177(12):1774\u201380.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"1645_CR12","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/s-0040-1714213","volume":"120","author":"D Abrahami","year":"2020","unstructured":"Abrahami D, Renoux C, Yin H, et al. The association between oral anticoagulants and cancer incidence among individuals with nonvalvular atrial fibrillation. Thromb Haemost. 2020;120(10):1384\u201394.","journal-title":"Thromb Haemost"},{"issue":"5","key":"1645_CR13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood-2010-08-304758","volume":"117","author":"V Pengo","year":"2011","unstructured":"Pengo V, Noventa F, Denas G, et al. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood. 2011;117(5):1707\u20139.","journal-title":"Blood"},{"issue":"12","key":"1645_CR14","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/aje\/kwr268","volume":"174","author":"TP Ahern","year":"2011","unstructured":"Ahern TP, Pedersen L, Sv\u00e6rke C, et al. The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol. 2011;174(12):1382\u201390.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"1645_CR15","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/ijc.27905","volume":"132","author":"A Potteg\u00e5rd","year":"2013","unstructured":"Potteg\u00e5rd A, Friis S, Hallas J. Cancer risk in long-term users of vitamin K antagonists: a population-based case-control study. Int J Cancer. 2013;132(11):2606\u201312.","journal-title":"Int J Cancer"},{"issue":"4","key":"1645_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.0370","volume":"178","author":"K Svendsen","year":"2018","unstructured":"Svendsen K, Karlstad \u00d8, Sm\u00e5brekke L. Lower cancer incidence: warfarin effect or immortal time bias? JAMA Intern Med. 2018;178(4):585.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1645_CR17","first-page":"1866","volume":"45","author":"DA Lawlor","year":"2016","unstructured":"Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. Int J Epidemiol. 2016;45(6):1866\u201386.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"1645_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1645_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14\u201320.","journal-title":"Clin Kidney J"},{"issue":"3","key":"1645_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","volume":"69","author":"MC Elze","year":"2017","unstructured":"Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. J Am Coll Cardiol. 2017;69(3):345\u201357.","journal-title":"J Am Coll Cardiol"},{"key":"1645_CR21","doi-asserted-by":"crossref","unstructured":"Powell EM, Douglas IJ, Gungabissoon U, Smeeth L, Wing K. Real-world effects of medications for stroke prevention in atrial fibrillation: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. BMJ Open 2021;11(4):e042947.","DOI":"10.1136\/bmjopen-2020-042947"},{"key":"1645_CR22","doi-asserted-by":"crossref","unstructured":"Rosendaal F, Cannegieter S, Van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb haemost. 1993;69(03):236\u201339.","DOI":"10.1055\/s-0038-1651587"},{"key":"1645_CR23","doi-asserted-by":"crossref","unstructured":"Leyrat C, Seaman SR, White IR, Douglas I, Smeeth L, Kim J, et al. Propensity score analysis with partially observed covariates: how should multiple imputation be used? Stat Methods Med Res. 2017;28(1):3\u201319.","DOI":"10.1177\/0962280217713032"},{"key":"1645_CR24","doi-asserted-by":"crossref","unstructured":"St\u00fcrmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution\u2014a simulation study. Am J epidemiol 2010;172(7):843\u201354.","DOI":"10.1093\/aje\/kwq198"},{"key":"1645_CR25","doi-asserted-by":"crossref","unstructured":"St\u00fcrmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570\u201380.","DOI":"10.1111\/joim.12197"},{"key":"1645_CR26","doi-asserted-by":"crossref","unstructured":"Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011;342:d1642.","DOI":"10.1136\/bmj.d1642"},{"issue":"2","key":"1645_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020485","volume":"15","author":"S Pati","year":"2023","unstructured":"Pati S, Irfan W, Jameel A, et al. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers. 2023;15(2):485.","journal-title":"Cancers"},{"issue":"3","key":"1645_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/PPO.0000000000000049","volume":"20","author":"CJ Rogers","year":"2014","unstructured":"Rogers CJ, Prabhu KS, Vijay-Kumar M. The microbiome and obesity: an established risk for certain types of cancer. Cancer J. 2014;20(3):176\u201380.","journal-title":"Cancer J"},{"issue":"5","key":"1645_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.15698\/cst2021.05.248","volume":"5","author":"X-Z Liu","year":"2021","unstructured":"Liu X-Z, Pedersen L, Halberg N. Cellular mechanisms linking cancers to obesity. Cell Stress. 2021;5(5):55.","journal-title":"Cell Stress"},{"issue":"3","key":"1645_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031436","volume":"19","author":"S Rogula","year":"2022","unstructured":"Rogula S, G\u0105secka A, Mazurek T, et al. Safety and efficacy of DOACs in patients with advanced and end-stage renal disease. Int J Environ Res Public Health. 2022;19(3):1436.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"1645_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3945\/ajcn.115.113548","volume":"102","author":"DL Streiner","year":"2015","unstructured":"Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity: whether and how to correct for many statistical tests. Am J Clin Nutr. 2015;102(4):721\u20138.","journal-title":"Am J Clin Nutr"},{"key":"1645_CR32","doi-asserted-by":"crossref","unstructured":"Grandjean P, Budtz-J\u00f8rgensen E, Keiding N, et al. Underestimation of risk due to exposure misclassification. Int J Occup Med Environ Health. 2004;17(1):131\u20136.","DOI":"10.1080\/10807030590920006"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01645-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:49:11Z","timestamp":1779202151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01645-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01645-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ian J. Douglas has shares in GSK and grants from GSK and AstraZeneca. Esther W.Y. Chan reports grants from Research Grants Council (RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda and Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region and an honorarium from the Hospital Authority, outside the submitted work. Celine S.L. Chui has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD and Amgen and personal fees from PrimeVigilance, outside the submitted work. Ian C.K. Wong reports research funding from Amgen, Bristol Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong Research Grants Council of the Government of the Hong Kong SAR, the Hong Kong Health and Medical Research Fund, the National Institute for Health Research in England, the European Commission, and the National Health and Medical Research Council in Australia, consulting fees from IQVIA and the World Health Organization, payment for expert testimony for the Appeal Court of Hong Kong and is a non-executive director of Jacobson Medical in Hong Kong, Advance Data Analytics for Medical Science (ADAMS) Limited (HK), Asia Medicine Regulatory Affairs (AMERA) Services Limited and OCUS Innovation Limited (HK, Ireland and UK), and a former director of Therakind in England, outside of the submitted work. Ian C.K. Wong reports roles as a member of Pharmacy and Poisons Board in Hong Kong, the Expert Committee on Clinical Events Assessment Following COVID-19 Immunisation and the Advisory Panel on COVID-19 Vaccines of the Hong Kong Government. Ian C.K. Wong is an Editorial Board member of\n                      Drug Safety\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Angel Y.S. Wong received an honorarium from 6th Annual Meeting of the Society for Clinical Epidemiology in Tokyo and the 28th Annual Meeting of the Japanese Society for Pharmacoepidemiology in Kyoto in November 2023, outside the submitted work. Zixuan Wang, Qiuyan Yu, Julian Matthewman, John Tazare, Sara Benitez Majano, Jeremy Brown, Ka Shing Cheung and Krishnan Bhaskaran have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study protocol was approved by the Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster for CDARS database research (Reference Number: UW 22-671), Clinical Practice Research Datalink Research Data Governance for CPRD database research (Reference Number: 21_001673) and London School of Hygiene and Tropical Medicine Ethics (Reference Number: 27923\u20111).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"As we used de-identified patient-level data routinely collected in the clinical setting, individual informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"As we used de-identified patient-level data routinely collected in the clinical setting, consent for publication was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The study data cannot be made available to other researchers because of the terms specified in data use agreements.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The computing code and study protocol are available from the corresponding author upon request for the purposes of reproducing the results.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ZW and AW had full access to the CPRD data while QY and CC had full access to the CDARS data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: ZW, ID, AW. Acquisition, analysis or interpretation of data: ZW, QY, CC, JT, ID, AW. Drafting of the manuscript: ZW, AW. Critical revision of the manuscript: all authors. Funding acquisition: IW, EC, CC, AW, ID. All authors have read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}